• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Doryx (doxycycline hyclate) Delayed-Release Tablets


 

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) --

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.

 

March 2011
 

Summary View

ADVERSE REACTIONS

Skin
  • erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis

 

June 2008

Summary View

Sections Modified

DRUG INTERACTIONS

  • Antacids and Iron Preparations

USE IN SPECIFIC POPULATIONS

  • Pediatric Use
  • Geriatric Use
  • Renal Impairment

PATIENT COUNSELING INFORMATION

  • All patients taking doxycycline should be advised:
    • that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron containing preparations...